Neurocrine Biosciences Inc. (NBIX)

Market Closed

17 Jul, 20:00

NASDAQ (NGS)

170. 88

-0.67

-0.3906%

17.3B Market Cap

63.27 P/E Ratio

- Div Yield

929,700 Volume

2.29 Eps

$ 171.55

Previous Close

Investors:

Analysts:

Add Transaction

Day Range

169.26 172.57

Year Range

122.14 181.18

Want to track NBIX and more in your Portfolio? 🎯

Get Started For Free

Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates?

Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks | 4 days ago

3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)

Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.

Zacks | 1 week ago

Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline

Biopharmaceutical firm Neurocrine Biosciences, Inc. (NBIX) up over 35% in a year and 17% since outlier inflows in May.

Fxempire | 1 week ago

Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Neurocrine (NBIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks | 1 week ago

Reasons Why Investors Should Consider Betting on Neurocrine Stock

NBIX builds on Ingrezza's momentum with pipeline advances and the Soleno acquisition, strengthening its long-term neuroscience growth strategy.

Zacks | 1 week ago

Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno

Neurocrine Biosciences, Inc. remains a Buy, driven by robust growth from Ingrezza, Crenessity, and the recent Vykat acquisition. Q1 2026 revenues rose 44% year-on-year to $811m, with Ingrezza and Crenessity annualizing at blockbuster levels and Vykat showing rapid ramp-up. NBIX stock valuation reflects high-growth expectations; forward P/S ~5.1x and P/E ~30x, justified by an expanding commercial portfolio and pipeline catalysts.

Seekingalpha | 2 weeks ago